Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Krishnan Swaminathan
+44 1382 632180
krishnan.swaminathan@nhs.net


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - The effects of spironolactone on endothelial function, autonomic function and glycaemic control in diabetic patients with poor blood pressure control
Back

The effects of spironolactone on endothelial function, autonomic function and glycaemic control in diabetic patients with poor blood pressure control

Not Recruiting

Open to: All Genders

Age: Not Specified

Dundee

Medical Conditions

Type 2 diabetes mellitus and hypertension

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Not provided at time of registration

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

01 Jan 2005 31 Dec 2006

Publications

2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18347776 results

Interventional

Intervention Type : Drug
Intervention Description : In this cross-over study, each participant was treated with two different drugs and a placebo, one at a time, in addition to his or her standard medication. Each drug / placebo treatment lasted for 4 weeks, and there was a 2-week washout period between each treatment (during the washout period participants took their standard medication only). Therefore, the entire duration of the intervention was 16 weeks. Details of the intervention treatments are as follows: 1. Spironolactone, 25 mg orally per day for 1 week, increased to 50 mg per day for the next 3 weeks if potassium levels were within normal limits (total duration of treatment 4 weeks) 2. Amlodipine, 5 mg orally per day for 4 weeks3. Placebo for 4 weeks




You can take part if:



You may not be able to take part if:


1. Blood pressure <140 mm Hg systolic and 80 mm Hg diastolic2. Recent admission to hospital within last 4 weeks3. History of alcohol abuse4. Liver or renal impairment5. Heart failure 6. On potassium sparing diuretics, insulin or warfarin (procedural risks)


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Department of Clinical Pharmacology
    Dundee
    DD1 9SY

This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.

Dr Krishnan Swaminathan
+44 1382 632180
krishnan.swaminathan@nhs.net



The study is sponsored by Tenovus Scotland (UK) and funded by Tenovus Scotland (ref: T03/21) (UK); Northwood Trust (UK).




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN76558770
Last updated 12 May 2011

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top